Biontech SE
BNTX106.620USD
+1.080+1.02%
Handelsschluss 02/06, 16:00（ET）Kurse um 15 Minuten verzögert
25.64BMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Biontech SE Unternehmen
BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
Biontech SE Informationen
BörsenkürzelBNTX
Name des UnternehmensBiontech SE
IPO-datumOct 10, 2019
CEOSahin (Ugur)
Anzahl der mitarbeiter6772
WertpapierartDepository Receipt
GeschäftsjahresendeOct 10
AddresseAn der Goldgrube 12
StadtMAINZ
BörseNASDAQ OMX - NASDAQ BASIC
LandGermany
Postleitzahl55131
Telefon4949613190840
Websitehttps://www.biontech.com/
BörsenkürzelBNTX
IPO-datumOct 10, 2019
CEOSahin (Ugur)
Führungskräfte von Biontech SE
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Sierk Poetting, Ph.D.
Dr. Sierk Poetting, Ph.D.
Chief Operating Officer, Member of the Management Board
Chief Operating Officer, Member of the Management Board
767.54K
+12755.00%
Dr. Ulrich Wandschneider, Ph.D.
Dr. Ulrich Wandschneider, Ph.D.
Independent Deputy Chairman of the Supervisory Board
Independent Deputy Chairman of the Supervisory Board
1.48K
--
Mr. James Ryan
Mr. James Ryan
Member of the Management Board, Chief Legal Officer
Member of the Management Board, Chief Legal Officer
790.00
+790.00%
Prof. Rudolf Staudigl, Ph.D.
Prof. Rudolf Staudigl, Ph.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
400.00
--
Prof. Anja Morawietz, Ph.D.
Prof. Anja Morawietz, Ph.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
240.00
--
Dr. Oezlem Tuereci, M.D.
Dr. Oezlem Tuereci, M.D.
Chief Medical Office, Member of the Management Board
Chief Medical Office, Member of the Management Board
--
--
Mr. Helmut Jeggle
Mr. Helmut Jeggle
Independent Chairman of the Supervisory Board
Independent Chairman of the Supervisory Board
--
--
Mr. Michael Motschmann
Mr. Michael Motschmann
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
--
--
Mr. Michael Horowicz
Mr. Michael Horowicz
Director, Investor Relations
Director, Investor Relations
--
--
Ms. Annemarie Hanekamp
Ms. Annemarie Hanekamp
Member of the Management Board, Chief Commercial Officer
Member of the Management Board, Chief Commercial Officer
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Sierk Poetting, Ph.D.
Dr. Sierk Poetting, Ph.D.
Chief Operating Officer, Member of the Management Board
Chief Operating Officer, Member of the Management Board
767.54K
+12755.00%
Dr. Ulrich Wandschneider, Ph.D.
Dr. Ulrich Wandschneider, Ph.D.
Independent Deputy Chairman of the Supervisory Board
Independent Deputy Chairman of the Supervisory Board
1.48K
--
Mr. James Ryan
Mr. James Ryan
Member of the Management Board, Chief Legal Officer
Member of the Management Board, Chief Legal Officer
790.00
+790.00%
Prof. Rudolf Staudigl, Ph.D.
Prof. Rudolf Staudigl, Ph.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
400.00
--
Prof. Anja Morawietz, Ph.D.
Prof. Anja Morawietz, Ph.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
240.00
--
Dr. Oezlem Tuereci, M.D.
Dr. Oezlem Tuereci, M.D.
Chief Medical Office, Member of the Management Board
Chief Medical Office, Member of the Management Board
--
--
Umsatzaufteilung
Währung: USDAktualisiert: Wed, Mar 12
Währung: USDAktualisiert: Wed, Mar 12
FY2019
FY2018
FY2017
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Collaboration Revenue
84.43M
77.75%
Revenues from Other Sales Transactions
24.16M
22.25%
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Nach Geschäftsbereich
Nach Region
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Collaboration Revenue
84.43M
77.75%
Revenues from Other Sales Transactions
24.16M
22.25%
Aktionärsstatistik
Aktualisiert: Mon, Feb 2
Aktualisiert: Mon, Feb 2
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
AT Impf GmbH
39.32%
Medine GmbH
15.49%
Fidelity Management & Research Company LLC
1.92%
T. Rowe Price Investment Management, Inc.
1.87%
Flossbach von Storch AG
1.62%
Andere
39.78%
Aktionäre
Aktionäre
Anteil
AT Impf GmbH
39.32%
Medine GmbH
15.49%
Fidelity Management & Research Company LLC
1.92%
T. Rowe Price Investment Management, Inc.
1.87%
Flossbach von Storch AG
1.62%
Andere
39.78%
Aktionärstypen
Aktionäre
Anteil
Corporation
55.45%
Investment Advisor
11.61%
Investment Advisor/Hedge Fund
3.54%
Individual Investor
1.95%
Research Firm
1.11%
Hedge Fund
0.98%
Sovereign Wealth Fund
0.71%
Pension Fund
0.16%
Bank and Trust
0.14%
Andere
24.35%
Institutionelle Beteiligung
Aktualisiert: Mon, Dec 8
Aktualisiert: Mon, Dec 8
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q4
771
54.72M
25.43%
-10.33K
2025Q3
808
54.84M
25.69%
-1.45M
2025Q2
821
56.21M
24.34%
+2.26M
2025Q1
832
54.17M
23.64%
-2.66M
2024Q4
855
52.85M
22.63%
+3.24M
2024Q3
827
49.68M
20.44%
+4.23M
2024Q2
801
45.24M
20.73%
+361.30K
2024Q1
817
44.34M
21.44%
-6.62M
2023Q4
879
44.00M
20.40%
+3.38M
2023Q3
904
40.73M
20.46%
-291.47K
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
AT Impf GmbH
101.85M
40.33%
-636.54K
-0.62%
Dec 31, 2024
Medine GmbH
40.13M
15.89%
-304.48K
-0.75%
Mar 31, 2025
Fidelity Management & Research Company LLC
4.98M
1.97%
-2.00M
-28.65%
Sep 30, 2025
T. Rowe Price Investment Management, Inc.
4.83M
1.91%
+1.24M
+34.32%
Sep 30, 2025
Flossbach von Storch AG
4.23M
1.68%
-65.00
-0.00%
Sep 30, 2025
PRIMECAP Management Company
3.87M
1.53%
-130.70K
-3.27%
Sep 30, 2025
Dodge & Cox
3.65M
1.44%
+2.77M
+315.65%
Sep 30, 2025
Sahin (Ugur MD)
2.05M
0.81%
-724.50K
-26.11%
Mar 31, 2025
Pfizer Inc
1.66M
0.66%
-2.00M
-54.67%
Sep 30, 2025
Temasek Holdings Pte. Ltd.
1.51M
0.6%
--
--
Sep 30, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Dec 6
Aktualisiert: Sat, Dec 6
Name
Anteil
Langar Global HealthTech ETF
4.06%
iShares Genomics Immunology and Healthcare ETF
3.6%
First Trust NYSE Arca Biotechnology Index Fund
3.42%
Global X Genomics & Biotechnology ETF
3.11%
WisdomTree BioRevolution Fund
2.74%
Franklin Genomic Advancements ETF
2.46%
VanEck Biotech ETF
2.38%
Virtus LifeSci Biotech Products ETF
1.58%
ProShares Ultra Nasdaq Biotechnology
1.02%
Invesco Nasdaq Biotechnology ETF
1.01%
Mehr Anzeigen
Langar Global HealthTech ETF
Anteil4.06%
iShares Genomics Immunology and Healthcare ETF
Anteil3.6%
First Trust NYSE Arca Biotechnology Index Fund
Anteil3.42%
Global X Genomics & Biotechnology ETF
Anteil3.11%
WisdomTree BioRevolution Fund
Anteil2.74%
Franklin Genomic Advancements ETF
Anteil2.46%
VanEck Biotech ETF
Anteil2.38%
Virtus LifeSci Biotech Products ETF
Anteil1.58%
ProShares Ultra Nasdaq Biotechnology
Anteil1.02%
Invesco Nasdaq Biotechnology ETF
Anteil1.01%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
